Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 54% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 3.3% — below-average profitability
REVVITY, INC. (RVTY) is a Healthcare company operating in Laboratory Analytical Instruments, listed on the NYSE , with a market capitalisation of $9.6 billion . Key value metrics: P/E ratio 40.5, P/B ratio 1.33, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
REVVITY, INC. — Fundamental Analysis Summary
REVVITY, INC. (RVTY) is currently trading 54% above its Graham Number of $55.64, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 40.5x.
On financial health, RVTY shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 3.3% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.36.
StockPik's composite Value Score for RVTY is 67/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
RVTY reports a solid gross margin of 55.2% (sector average: 33.5%) and a solid operating margin of 12.4%.
RVTY shows revenue growing at 4% year-over-year, with earnings declining at 11%.
RVTY pays a modest dividend yield of 0.3%.